Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed
A phase 2 trial of PF-08634404 in small-cell lung cancer, run by Pfizer, now recruiting.
Overview
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07476287 by Pfizer, with 40 participants planned, started 2026-07-02 and due to reach its primary completion in 2028-03-19. Interventions recorded: PF-08634404, Chemotherapy. Conditions listed: Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer.
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares PF-08634404, Pfizer (incl. Seagen).
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares PF-08634404, Pfizer (incl. Seagen).
- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares PF-08634404, Pfizer (incl. Seagen).
- TrialSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares PF-08634404, Pfizer (incl. Seagen).
- TrialSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a
Shares PF-08634404, Pfizer (incl. Seagen).
- TrialThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu